Samsung Bioepis has succeeded in making a performance rebound and overcoming the unfavorable factors from COVID-19. Despite the pandemic, sales of its biosimilars that are being sold globally through overseas partners, have steadily increased to serve as a reliable source of performance.

According to the Financial Supervisory Service on the 19th, Samsung Bioepis recorded ₩187.5 billion in sales in Q2, which is a 22.7% year-on-year increase. The company had continued on a downward roll since Q3 of last year, when it recorded its all-time high with ₩236.9 billion, however, in only 2 quarters since then, the company has recovered its performance to a level similar to its pre-COVID-19 performance.